Insider buying last 90 days
No open-market insider purchases were filed for CRL in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every CRL insider filing, plotted on the chart in Gekko.Open CRL in Gekko
NYSE: CRL
Charles River Laboratories International (CRL) Stock Analysis & Forecast
Sep 28 close
$294.59+1.75 (+0.6%)
Gekko Brief
AI summaryCharles River Laboratories held its 2026 Investor Day this week, reaffirming 2026 guidance for organic revenue growth and non-GAAP earnings per share at the upper end of prior ranges and unveiling a strategy through 2030 targeting 5% to 7% organic revenue growth, roughly 24% non-GAAP operating margin, low double-digit non-GAAP EPS growth, and $300 million in savings, with AI and automation cited as drivers. The event drew a string of analyst price target increases: Barclays raised its target to $330 from $300 with an Overweight rating, RBC to $322 from $282 with Outperform, and Mizuho to $295 from $264 while keeping a Neutral rating. Coverage also noted the stock's outperformance versus the S&P 500 over the past year.
Shares closed at $294.59, up 0.6%, sitting above both the 50-day ($270.45) and 200-day ($208.03) averages, with the 50-day above the 200-day. The GekkoIndex reads 52.3, placing CRL in the Neutral zone, down from a five-day change of -5.5. Price sits 23.5% above Gekko Fair Value of $238.52.
The next earnings report is due 4 November 2026, before the open, 36 days out and beyond a typical 20-day holding window; the prior quarter beat estimates ($3.02 versus $2.74) with a 13.4% reaction. Over the last 30 days there have been 2 unusual options signals, with put premium of $1,074,125 against call premium of $267,960. Consensus among 16 firms stands at 14 buy, 2 hold, 0 sell, with a $298.79 target. Seasonally, the next 20 trading days have averaged +6.1% over 5 years, rising in 2 of them.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Charles River Laboratories International price vs fair value
Close $294.59200-day averageGekko Fair Value $238.52
Charles River Laboratories International quick facts
- Market cap
- $14.19B
- P/E ratio
- —
- Forward P/E
- 22.4
- EPS, TTM
- −$4.80
- Revenue, TTM
- $4.00B
- Profit margin
- -6%
- Dividend yield
- —
- Beta
- 1.41
- Volume
- 899,980 avg 969,461
- 1-year return
- +102.4%
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±7.9%
- 50-day average
- $270.45
- 200-day average
- $208.03
- Next earnings
- Nov 4 before open
- Shares outstanding
- 48.17M
Charles River Laboratories International swing-trade checklist
Charles River Laboratories International scores 2 supportive, 2 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed2 headwinds
- Trendsupportive
Above 50 and 200-day
Close $294.59 is above the 50-day ($270.45) and 200-day ($208.03) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
52.3, Neutral
Reading 52.3 is in the Neutral zone.
See the GekkoIndex - Fair valueheadwind
23.5% above
Price is 23.5% above Gekko Fair Value (more than 5% above).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 2 unusual options signals.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+6.1% on average
From this point in the calendar, the next 20 trading days averaged +6.1% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Charles River Laboratories International stock chart and price history
Charles River Laboratories International closed at $294.59 on Sep 28, 2026, +102.4% over the past year, inside a 52-week range of $145.32 to $303.31.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −0.6%
- 3 months
- +30.6%
- 6 months
- +85.1%
- 1 year
- +102.4%
The full CRL chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open CRL in Gekko
Follow Charles River Laboratories International through every session
Put CRL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track CRL in GekkoFree for 7 days. No credit card required.
About Charles River Laboratories International
Charles River Laboratories International serves pharmaceutical and biotechnology firms by acting as an outside research partner for the early stages of drug development. Clients turn to it for help discovering new compounds, running non-clinical studies, and confirming that candidate drugs are safe before moving forward, and it has built a name for breeding and supplying laboratory rats and mice used in that experimentation.
Its work is split across three business areas. One focuses on producing research-grade rodents, including genetically modified strains, and on services that help laboratories manage animal colonies, outsource facility operations, and run diagnostics on research animals. Another concentrates on the science behind early drug development, helping clients pinpoint and confirm promising targets, molecules, and antibodies, then evaluating them through toxicology work, pathology review, safety pharmacology, bioanalysis, metabolic profiling, and pharmacokinetic analysis. A third handles testing tied to manufacturing, checking the sterility and quality of drugs and consumer goods, performing specialized biologics testing on behalf of client companies, and supplying materials used in vaccine production, such as disease-free eggs and birds along with related diagnostic tools. Beyond these three areas, the company also operates animal housing facilities under contract for biopharmaceutical clients, and its client base spans the United States, Europe, Canada, and Asia Pacific.
Its shares trade on the NYSE under the ticker CRL.
- Listed
- NYSE
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Website
- criver.com
Charles River Laboratories International GekkoIndex: the smart money zone
Charles River Laboratories International’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.3, in the Neutral zone, down 5.5 points over five sessions.
52.3Neutral
Down 5.5 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 45 | −0.7% | +3.2% | ||
| Accumulation | 245 | +1.1% | +2.9% | ||
| Neutral (current zone) | 316 | +0.3% | +1.1% | ||
| Distribution | 59 | −0.5% | −1.5% | ||
| Selling | 7 | Too few readings yet | |||
Average CRL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the CRL price, zone by zone.Track CRL in Gekko
Is Charles River Laboratories International stock overvalued? Gekko Fair Value
Charles River Laboratories International trades 23.5% above Gekko Fair Value of $238.52, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Charles River Laboratories International shares are worth, recalculated every trading day.
$238.52
Gekko Fair Value, Sep 29, 2026
23.5% Overvalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open CRL in Gekko
Charles River Laboratories International insider and Congress trading
No open-market insider purchases were filed for Charles River Laboratories International, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in CRL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for CRL, plotted on the chart in Gekko.Open CRL in Gekko
Buybacks
Charles River Laboratories International has been buying back its own shares.
- Bought back, quarter ended Jun 27, 2026
- $115.6M
- As a share of market cap
- 0.81%
- Trailing four quarters
- $324.1M
From company filings.
Unusual options activity last 30 days
2signals, 20% of the flagged premium in calls.
Latest: Bullish flow on Sep 18, $268K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold CRL.
0added0opened0trimmed2sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Charles River Laboratories International earnings: next date and track record
Charles River Laboratories International reports on Nov 4, 2026, before the open (36 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected before the open, 36 days away
- EPS estimate
- $2.96
- Revenue estimate
- $959.1M
8 of 8reports beat the EPS estimate
±9.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 5, 2026 AI summary
- What they said
- Charles River Labs beat Q2 2026 targets and raised full-year guidance. DSA net book-to-bill rose to ~1.2x, the third consecutive quarter above 1.0x and highest in nearly 4 years. Total company returned to organic revenue growth at 0.1%, first positive organic growth since Q3 2023. Operating margin improved 420 basis points sequentially to 20.5%, aided by divestitures of European discovery services, CDMO, and Cell Solutions businesses. A new collaboration with Eli Lilly's TuneLab AI platform was announced.
- Guidance
- Management raised full-year 2026 financial guidance following Q2 outperformance. The company expects accelerating organic revenue growth in H2 2026, supported by strengthening biopharmaceutical demand and a streamlined post-divestiture portfolio.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | $3.02 est $2.74 | $1.00B est $977.2M | +13.4% |
| May 7, 2026 | $2.06 est $1.96 | $995.8M est $977.5M | −2.3% |
| Feb 18, 2026 | $2.39 est $2.35 | $994.2M est $987.0M | +3.6% |
| Nov 5, 2025 | $2.43 est $2.32 | $1.00B est $987.2M | −3.9% |
| Aug 6, 2025 | $3.12 est $2.50 | $1.03B est $968.9M | −10.6% |
| May 7, 2025 | $2.34 est $2.06 | $984.2M est $958.8M | +22.5% |
| Feb 19, 2025 | $2.66 est $2.50 | $1.00B est $948.2M | +5.1% |
| Nov 6, 2024 | $2.59 est $2.42 | $1.01B est $976.0M | +11.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Charles River Laboratories International stock forecast and analyst price targets
Analysts’ average 12-month price target for Charles River Laboratories International is $298.79, +1.4% from the last close, from 16 firms rating the stock in the last 90 days.
$298.79consensus 12-month target, +1.4% from the last close
Now $294.59Avg $298.79
Low $219High $340
Each firm’s latest rating in the last 90 days: 16 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Jefferies | $340 | +15.4% |
| Sep 28 | Bank of America Securities | — | — |
| Sep 25 | Deutsche Bank | $320 | +8.6% |
| Sep 25 | Robert W. Baird | $334 | +13.4% |
| Sep 25 | Evercore ISI | $330 | +12.0% |
+1.1%average 20-day move after past Neutral readings
+6.1%average move over the next 20 trading days in the last 5 years
±3.4%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Charles River Laboratories International seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Charles River Laboratories International averaged +6.1% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.0% | 2 of 5 |
| Next 10 trading days | +2.7% | 3 of 5 |
| Next 15 trading days | +5.4% | 3 of 5 |
| Next 20 trading days | +6.1% | 2 of 5 |
| Next 30 trading days | +5.3% | 3 of 5 |
For scale, CRL’s typical 20-trading-day move in either direction is about 7.9%.
Charles River Laboratories International market cap and key statistics
Charles River Laboratories International’s market cap is $14.19B and revenue of $4.00B over the last twelve months.
Valuation
- Market cap
- $14.19B
- Forward P/E
- 22.4
- EPS, TTM
- −$4.80
- Gekko Fair Value
- $238.52
Trading
- Volume
- 899,980
- Avg volume, 20 days
- 969,461
- 52-week high
- $303.31
- 52-week low
- $145.32
- Shares outstanding
- 48.17M
Financials
- Revenue, TTM
- $4.00B
- Profit margin
- -6%
- Return on equity
- -7.5%
- Quarterly earnings growth, YoY
- −17.3%
Risk and income
- Beta
- 1.41
- Typical daily move
- ±3.4%
- Typical 20-day move
- ±7.9%
Charles River Laboratories International stock news this week
Coverage of Charles River Laboratories International this week reads positive: 18 positive, 2 neutral and 1 negative headlines.
- Charles River Laboratories stock at USD 294.59 on September 28, 2026AD HOC NEWS, Sep 28
- Should Long Term Growth Targets Require Action From Charles River Labs Stock Investors?Simply Wall Street, Sep 27
- Is Charles River Laboratories Stock Outperforming the S&P 500?inkl, Sep 27
- Barclays Adjusts PT on Charles River Laboratories International to $330 From $300, Keeps Overweight RatingMoomoo, Sep 26
- Charles River Targets 5%-7% Growth, $300M Savings in 2030 PlanMarketBeat, Sep 25
- Charles River Laboratories International, Inc. (CRL) Latest Stock News & Headlines - Yahoo FinanceYahoo! Finance Canada, Sep 25
Charles River Laboratories International peers
Charles River Laboratories International’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| SHOPShopify | Neutral | 5.0% above |
| CTASCintas | Neutral | 11.5% above |
| PYPLPayPal | Accumulation | 4.6% below |
| XYZBlock | Accumulation | 2.5% above |
| CPAYCorpay | Accumulation | 18.1% below |
| FISVFiserv | Buying | 40.6% below |
A peer links to its own page where one exists.
Charles River Laboratories International stock FAQ
What is Charles River Laboratories International’s market cap?
Charles River Laboratories International’s market cap is $14.19B at the Sep 28, 2026 close of $294.59, with 48.17M shares outstanding.
What is the Charles River Laboratories International stock forecast?
The consensus analyst 12-month price target for Charles River Laboratories International is $298.79, +1.4% from the last close. Of the 16 firms that rated the stock in the last 90 days, 14 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Charles River Laboratories International stock overvalued or undervalued?
On Gekko’s estimate Charles River Laboratories International is overvalued: the Sep 28, 2026 close of $294.59 is 23.5% above Gekko Fair Value of $238.52. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Charles River Laboratories International report earnings next?
Charles River Laboratories International is expected to report on Nov 4, 2026, before the market opens (36 days away). Analysts expect earnings of $2.96 per share on revenue of $959.1M. Charles River Laboratories International beat the earnings estimate in 8 of its last 8 reports, moving 9.1% on average across the report.
What is Charles River Laboratories International’s 52-week high and low?
Charles River Laboratories International’s 52-week high is $303.31 and its 52-week low is $145.32; it closed at $294.59 on Sep 28, 2026, +102.4% over the past year. Over the last five years the shares peaked at $449.34 on Oct 29, 2021.
Is Charles River Laboratories International stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 6 items with data read as supportive (trend and earnings risk), 2 as mixed (gekkoindex and seasonality) and 2 as headwinds (fair value and smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Charles River Laboratories International?
Gekko flagged 2 unusual options signals in Charles River Laboratories International over the last 30 days, with $268K of flagged premium in calls and $1.07M in puts. The latest, bullish flow, was on Sep 18, 2026 with $268K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Charles River Laboratories International the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.